← Human Trials & Peer-Reviewed Studies
The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
Plain-language guide to PMID 36034448 (2022): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 43 children.
Key Facts
- PMID
- 36034448
- Journal
- Frontiers in endocrinology
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Liang Y et al. (16 authors)
- DOI
- 10.3389/fendo.2022.922304
- Registered trial
- NCT04513171
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Who Took Part
The abstract describes 43 children taking part.
The age groups tagged for this paper are children.
The treatment lasted 12 weeks.
The secondary outcome was the height velocity (HV) increment at week 12.
How the Study Was Run
In design terms this was a randomized, double-blind and multicenter study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the children and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.
The primary outcome was the area under the curve of the change of insulin-like growth factor-1 (IGF-1).
What Was Measured
The subject headings attached to it are Dwarfism, Pituitary, Human Growth Hormone, Insulin-Like Growth Factor I, Polyethylene Glycols and Recombinant Proteins.
Author keywords: Y-shape branched PEGylation, clinical trial, growth hormone deficiency, long-acting growth hormone and prepubertal children.
What This Means in Plain Language
The paper is a randomized, double-blind and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 43 children.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Frontiers in endocrinology), a journal based in Switzerland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.